[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015006217A - Dispersible tablet. - Google Patents

Dispersible tablet.

Info

Publication number
MX2015006217A
MX2015006217A MX2015006217A MX2015006217A MX2015006217A MX 2015006217 A MX2015006217 A MX 2015006217A MX 2015006217 A MX2015006217 A MX 2015006217A MX 2015006217 A MX2015006217 A MX 2015006217A MX 2015006217 A MX2015006217 A MX 2015006217A
Authority
MX
Mexico
Prior art keywords
dispersible tablet
tablet
nimorazole
dispersion
patient
Prior art date
Application number
MX2015006217A
Other languages
Spanish (es)
Inventor
Nilesh Tanhaji Dumbre
Mahesh Mohanrao Bhadgale
Vardhaman Chandrakant Bafna
Original Assignee
Azanta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK201270714A external-priority patent/DK177906B1/en
Priority claimed from US13/680,216 external-priority patent/US8703188B1/en
Application filed by Azanta As filed Critical Azanta As
Publication of MX2015006217A publication Critical patent/MX2015006217A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt thereof, for dispersion in water and administration via a tube to a patient with swallowing difficulties.
MX2015006217A 2012-11-19 2013-11-18 Dispersible tablet. MX2015006217A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK201270714A DK177906B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
US13/680,216 US8703188B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
PCT/DK2013/050384 WO2014075692A1 (en) 2012-11-19 2013-11-18 Dispersible tablet

Publications (1)

Publication Number Publication Date
MX2015006217A true MX2015006217A (en) 2015-11-16

Family

ID=49683383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006217A MX2015006217A (en) 2012-11-19 2013-11-18 Dispersible tablet.

Country Status (12)

Country Link
EP (1) EP2919754A1 (en)
JP (1) JP2015537013A (en)
AU (1) AU2013347264B2 (en)
BR (1) BR112015011408A2 (en)
CA (1) CA2888856A1 (en)
EA (1) EA201590732A1 (en)
MX (1) MX2015006217A (en)
NZ (1) NZ707033A (en)
RU (1) RU2015117921A (en)
TN (1) TN2015000156A1 (en)
WO (1) WO2014075692A1 (en)
ZA (1) ZA201502896B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016212116B2 (en) * 2015-01-27 2021-07-15 Janssen Pharmaceutica Nv Dispersible compositions
TWI718138B (en) 2015-04-01 2021-02-11 美商阿克比治療有限公司 Compositions and methods for treating anemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin
JP2008081448A (en) * 2006-09-28 2008-04-10 Kowa Pharmaceutical Co Ltd Bitterness masking rapid release particle of zolpidem tartrate
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
EP2510950B1 (en) * 2009-12-11 2018-11-28 Sumitomo Dainippon Pharma Co., Ltd. Dry-coated orally disintegrating tablet
KR20130100892A (en) * 2010-04-14 2013-09-12 유파마 피티와이 엘티디 Radiation sensitiser compositions

Also Published As

Publication number Publication date
WO2014075692A1 (en) 2014-05-22
AU2013347264B2 (en) 2016-10-27
TN2015000156A1 (en) 2016-10-03
AU2013347264A1 (en) 2015-05-07
BR112015011408A2 (en) 2017-07-11
JP2015537013A (en) 2015-12-24
NZ707033A (en) 2016-11-25
EP2919754A1 (en) 2015-09-23
EA201590732A1 (en) 2016-01-29
CA2888856A1 (en) 2014-05-22
RU2015117921A (en) 2017-01-10
ZA201502896B (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
MX369121B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
EP3904502A3 (en) Compositions and methods
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX366090B (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
MX344846B (en) Combination of active loaded granules with additional actives.
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IN2015DN02999A (en)
TN2015000156A1 (en) Dispersible tablet
MX2013010947A (en) Gallium complexes, pharmaceutical compositions and methods of use.
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
MX2016011706A (en) Progesterone formulations.
SA515360445B1 (en) Dispersible tablet
DK201270714A (en) Dispersible tablet
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
HK1207969A1 (en) Pharmaceutical composition for oral administration with improved dissolution and or absorption
UA105513C2 (en) Glucosamine prolonged release dosage form
UA56353U (en) method for restoration of tear-nasal canal in children with administration of drug